Park Medi World shares jumped 10% following Emkay Research's 'Buy' rating and ₹350 target price, implying around 35% upside from current levels. According to LiveMint, the stock closed at ₹278.25 per share on the BSE, demonstrating strong investor confidence despite broader market weakness. Emkay Research initiated coverage of the hospital chain with the buy recommendation, positioning the stock for potential significant gains based on its operational efficiency and expansion strategy.
Park's competitive advantage lies in its differentiated business model that combines quality healthcare with affordability, enabling it to serve the underserved mass market. As reported by Emkay Research, the company's lean cost structure and high asset utilisation create a virtuous cycle of profitability and superior return ratios. The brokerage noted that Park has one of the lowest capital expenditure requirements per bed in the industry, at around ₹3.2 million. Its efficient hospital design, higher patient volumes and cluster-based operating model enable better utilisation of assets and clinical resources while maintaining healthy margins.
The management's demonstrated execution capabilities are evident in the company's acquisition turnaround strategy, where acquired hospitals contributed nearly 62% of the company's FY26 EBITDA. According to Emkay Research, this agility allows for rapid scale without compromising capital expenditure discipline. The company maintains a strong balance sheet with net cash of approximately ₹200 crore and healthy cash conversion with FY26 OCF/EBITDA ratio of 74%. Emkay Research values the company at 21x Mar-28E EV/EBITDA, in line with sector averages.
Park has identified a robust pipeline of approximately 2,200 beds representing around 60% of FY26 capacity, as reported by Emkay Research. The company's strategic roadmap includes expansion into high-demand, underpenetrated markets such as Uttar Pradesh. Based on this growth trajectory, Emkay Research expects Park to achieve 24%/23% revenue/EBITDA CAGR over FY26-29, driven by capacity additions, operating leverage, improving payer mix and benefits from government healthcare pricing revisions. The brokerage believes the company's ability to scale rapidly without compromising capital discipline provides a significant competitive advantage.
Emkay Research expects the company's improving working capital cycle and strong fundamentals to drive a re-rating of the stock. The brokerage highlighted Park's healthy financial position, including its net cash balance of approximately ₹200 crore, robust operating cash flow generation and an improving working capital cycle. While key risks include delays in ramping up new facilities and slower collections from government healthcare schemes, Emkay Research believes the combination of affordability, scalability and disciplined expansion could support a re-rating of the stock over the medium term. The proposed asset-light operations and management (O&M) strategy in new geographies could reduce execution risks and improve returns.
